Contribute Try STAT+ Today
Trending:
Adam's Take
Coronavirus
Biotech
Health

Latest

Delivering must-read stories about health, medicine, and scientific discovery

orange electron micrograph
Morning Rounds

India to open vaccination to all adults, what experts still want to know about Covid-19, & a new book explores the Sackler family

By Shraddha Chakradhar

voice tech
Health Tech

The future of voice tech in medicine is here. Can reality live up to the promise?

By Katie Palmer

Illumina Grail vertical merger
First Opinion

FTC’s challenge to Illumina’s vertical merger with Grail is all wrong

By Joe Lonsdale

Covid-19 swabs
First Opinion

Catching Covid-19 after being vaccinated isn’t a myth. It happened to me

By Stephen M. Tourjee

Patrick Radden Keefe
Health

A new book traces the roots of the opioid crisis through the secretive Sackler family

By Andrew Joseph

1/21 executive order
Exclusive

Biden officials met privately with 3M, AmerisourceBergen, PhRMA, and more to debate shoring up the national stockpile 

By Nicholas Florko

SARS-CoV-2 virus particle
Health

We know a lot about Covid-19. Experts have many more questions

By Helen Branswell

Cash on yellow background
Biotech

Adagio raises $336 million to advance Covid-19 antibody treatment

By Anissa Gardizy — Boston Globe

Pharmalot

Pharmalittle: J&J denies design of its Covid-19 shot may explain blood clots; second trial against opioid makers begins

By Ed Silverman

pill dollar sign list price
Pharmalot

Advocacy groups outraged after a PBM offers a $500 gift card to persuade patients to switch drugs

By Ed Silverman

The READOUT
The Readout

Covid spaghetti, more on J&J’s pause, & remote FDA inspections

By Meghana Keshavan

Kamala Harris
Morning Rounds

VP Harris calls for urgent action on Black maternal health, the AHA loses its top lobbyist, & Biden’s $1.7B plan to track Covid-19 variants

By Erin Brodwin

remote inspection
Opinions+

The FDA should embrace remote and automated drug inspection technology

By Patrick McLaughlin and Tyler Richards

for-profit nursing homes
First Opinion

For-profit nursing homes and hospices are a bad deal for older Americans

By Haider J. Warraich

Tom Nickels
Politics

The lobbying juggernaut the American Hospital Association is losing its top advocate at a critical moment for the industry

By Rachel Cohrs

VP Harris
Health

In Q&A, Vice President Harris calls for urgent action on the Black maternal health crisis 

By Nicholas St. Fleur

dark room/child abuse
Health

New report offers guidance for pediatricians on how to prevent abuse of children with disabilities

By Rebecca Sohn

Andersonville Prison
First Opinion

Lessons learned — and forgotten — from the horrific epidemics of the U.S. Civil War

By Jonathan S. Jones

Pharmalot Coming/Going STILL
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: J&J rivals rebuff bid to jointly study Covid-19 vaccine risks; will next-gen Covid shots be better or worse?

By Ed Silverman

The READOUT
The Readout

Biotech’s mixed record on Covid-19, FDA frustrates ALS advocates, & a rebranded unicorn

By Damian Garde

antibiotics/teal background
Morning Rounds

First chimeric human-monkey embryos, need for new antibiotics, & barriers to care for transgender women

By Katie Palmer

Treatment research
The Readout LOUD

‘We did need to throw a lot of spaghetti against the Covid window’: a biotech analyst on pandemic drug development

By Meg Tirrell, Damian Garde, and Adam Feuerstein

Fecal microbiota transplantation
First Opinion

Developers of microbiome-based drugs face challenges. There are ways to overcome them

By Andrew Thomson, Brian Carpenter, and Robert Broadnax

ketogenic diet
First Opinion

A ketogenic diet brought me back to life. Will believing in its effectiveness make me a pariah in medical school?

By Nicholas Norwitz

Health

Next-generation Covid-19 vaccines are supposed to be better. Some experts worry they could be worse

By Helen Branswell

Gavel black background lawsuits
Pharmalot

A drug maker sues a medical journal, its editor, and several authors for libel

By Ed Silverman

Play
The Readout LOUD

Listen: J&J’s vaccine pause, how to talk about remote risks, & why we don’t have new drugs for Covid-19

By Damian Garde, Meg Tirrell, and Adam Feuerstein

Thermo Fisher Scientific
Biotech

Thermo Fisher buys contract-research company PPD for $17.4 billion

By Anissa Gardizy — Boston Globe